Pharmacological Intervention to Modulate HDL: What Do We Target?

Overview

Journal Front Pharmacol

Date 2018 Feb 7

PMID 29403378

Citations 33

Authors

Nicholas J Woudberg

Sarah Pedretti

Sandrine Lecour

Rainer Schulz

Nicolas Vuilleumier

Richard W James

Miguel A Frias

Affiliations

Soon will be listed here.

Abstract

The cholesterol concentrations of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) have traditionally served as risk factors for cardiovascular disease. As such, novel therapeutic interventions aiming to raise HDL cholesterol have been tested in the clinical setting. However, most trials led to a significant increase in HDL cholesterol with no improvement in cardiovascular events. The complexity of the HDL particle, which exerts multiple physiological functions and is comprised of a number of subclasses, has raised the question as to whether there should be more focus on HDL subclass and function rather than cholesterol quantity. We review current data regarding HDL subclasses and subclass-specific functionality and highlight how current lipid modifying drugs such as statins, cholesteryl ester transfer protein inhibitors, fibrates and niacin often increase cholesterol concentrations of specific HDL subclasses. In addition this review sets out arguments suggesting that the HDL3 subclass may provide better protective effects than HDL2.

Citing Articles

Lipidomics of Huntington's Disease: A Comprehensive Review of Current Status and Future Directions.

Yilmaz A, Akyol S, Ashrafi N, Saiyed N, Turkoglu O, Graham S Metabolites. 2025; 15(1).

PMID: 39852353 PMC: 11766911. DOI: 10.3390/metabo15010010.

Enhancing Wound Healing and Anti-Inflammatory Effects by Combination of CIGB-258 and Apolipoprotein A-I against Carboxymethyllysine Toxicity in Zebrafish: Insights into Structural Stabilization and Antioxidant Properties.

Cho K, Lee Y, Lee S, Kim J, Bahuguna A, Dominguez-Horta M Antioxidants (Basel). 2024; 13(9).

PMID: 39334708 PMC: 11428460. DOI: 10.3390/antiox13091049.

Blood Lipoproteins Shape the Phenotype and Lipid Content of Early Atherosclerotic Lesion Macrophages: A Dual-Structured Mathematical Model.

Chambers K, Myerscough M, Watson M, Byrne H Bull Math Biol. 2024; 86(9):112.

PMID: 39093509 PMC: 11297092. DOI: 10.1007/s11538-024-01342-9.

High-Density Lipoprotein Signaling via Sphingosine-1-Phosphate Receptors Safeguards Spontaneously Hypertensive Rats against Myocardial Ischemia/Reperfusion Injury.

Al-Jarallah A, Babiker F Pharmaceutics. 2024; 16(4).

PMID: 38675158 PMC: 11054943. DOI: 10.3390/pharmaceutics16040497.

Profile of Lipoprotein Subclasses in Chinese Primary Open-Angle Glaucoma Patients.

Fu C, Xu J, Chen S, Chen C, Liang J, Liu Z Int J Mol Sci. 2024; 25(8).

PMID: 38674129 PMC: 11050298. DOI: 10.3390/ijms25084544.

References

Van Craeyveld E, Gordts S, Nefyodova E, Jacobs F, De Geest B . Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med (Berl). 2011; 89(6):555-67. PMC: 3098380. DOI: 10.1007/s00109-011-0722-x. View

Sattler K, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler M . Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol. 2010; 105(6):821-32. DOI: 10.1007/s00395-010-0112-5. View

Kontush A, Chantepie S, Chapman M . Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003; 23(10):1881-8. DOI: 10.1161/01.ATV.0000091338.93223.E8. View

Morgan J, Capuzzi D, Baksh R, Intenzo C, Carey C, Reese D . Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003; 91(12):1432-6. DOI: 10.1016/s0002-9149(03)00394-1. View

Tian L, Li C, Liu Y, Chen Y, Fu M . The value and distribution of high-density lipoprotein subclass in patients with acute coronary syndrome. PLoS One. 2014; 9(1):e85114. PMC: 3900409. DOI: 10.1371/journal.pone.0085114. View

Damirin A, Tomura H, Komachi M, Tobo M, Sato K, Mogi C . Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol. 2004; 67(4):1177-85. DOI: 10.1124/mol.104.004317. View

Cabana V, Lukens J, Rice K, HAWKINS T, Getz G . HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res. 1996; 37(12):2662-74. View

Neuman M, Neuman H, NEUMAN J . Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment. Atherosclerosis. 1991; 91 Suppl:S11-9. DOI: 10.1016/0021-9150(91)90202-e. View

Frias M, Lecour S, James R, Pedretti S . High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT. 2013; 1(2):92-100. PMC: 3670301. DOI: 10.4161/jkst.19754. View

10.

Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Bastardot F . Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study. Thromb Haemost. 2016; 116(4):764-71. DOI: 10.1160/TH16-03-0248. View

11.

Ditah C, Otvos J, Nassar H, Shaham D, Sinnreich R, Kark J . Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample. Atherosclerosis. 2016; 251:124-131. DOI: 10.1016/j.atherosclerosis.2016.06.010. View

12.

Luscher T, Landmesser U, von Eckardstein A, Fogelman A . High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014; 114(1):171-82. DOI: 10.1161/CIRCRESAHA.114.300935. View

13.

Millar J, Cuchel M . ApoA-I-Directed Therapies for the Management of Atherosclerosis. Curr Atheroscler Rep. 2015; 17(10):60. DOI: 10.1007/s11883-015-0539-0. View

14.

Ishikawa T, Ayaori M, Uto-Kondo H, Nakajima T, Mutoh M, Ikewaki K . High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. Atherosclerosis. 2015; 242(1):318-22. DOI: 10.1016/j.atherosclerosis.2015.06.028. View

15.

Ruotolo G, Ericsson C, Tettamanti C, Karpe F, Grip L, Svane B . Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention.... J Am Coll Cardiol. 1998; 32(6):1648-56. DOI: 10.1016/s0735-1097(98)00442-2. View

16.

Cheung M, Austin M, Moulin P, Wolf A, Cryer D, Knopp R . Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 1993; 102(1):107-19. DOI: 10.1016/0021-9150(93)90089-d. View

17.

Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J . Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost. 2009; 101(4):665-73. View

18.

Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis D, Rizzo M . The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013; 19(17):3124-31. DOI: 10.2174/1381612811319170020. View

19.

Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I . High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006; 114(13):1403-9. DOI: 10.1161/CIRCULATIONAHA.105.607135. View

20.

Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H . Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis. 1995; 114(2):223-34. DOI: 10.1016/0021-9150(94)05487-4. View